IDEXX Laboratories, Inc. (NASDAQ:IDXX) CEO Jonathan W. Ayers sold 2,160 shares of the company’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $167.03, for a total transaction of $360,784.80. Following the completion of the transaction, the chief executive officer now owns 1,077,112 shares of the company’s stock, valued at approximately $179,910,017.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

IDEXX Laboratories, Inc. (NASDAQ IDXX) traded up $0.96 on Friday, hitting $172.47. 189,372 shares of the company traded hands, compared to its average volume of 464,250. IDEXX Laboratories, Inc. has a 52-week low of $116.54 and a 52-week high of $173.01. The company has a debt-to-equity ratio of -12.48, a quick ratio of 0.77 and a current ratio of 0.95. The firm has a market cap of $14,990.00, a P/E ratio of 56.00, a PEG ratio of 2.29 and a beta of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The firm had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same quarter in the prior year, the firm earned $0.62 EPS. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. sell-side analysts expect that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. National Asset Management Inc. raised its position in shares of IDEXX Laboratories by 2.1% during the 2nd quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after purchasing an additional 42 shares during the last quarter. Advisor Group Inc. raised its position in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Advisor Group Inc. now owns 4,998 shares of the company’s stock worth $732,000 after purchasing an additional 52 shares during the last quarter. QS Investors LLC raised its position in shares of IDEXX Laboratories by 1.5% during the 2nd quarter. QS Investors LLC now owns 4,068 shares of the company’s stock worth $657,000 after purchasing an additional 60 shares during the last quarter. Thrivent Financial For Lutherans raised its position in shares of IDEXX Laboratories by 3.1% during the 2nd quarter. Thrivent Financial For Lutherans now owns 3,340 shares of the company’s stock worth $539,000 after purchasing an additional 100 shares during the last quarter. Finally, Ropes Wealth Advisors LLC raised its position in shares of IDEXX Laboratories by 4.1% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 5,040 shares of the company’s stock worth $814,000 after purchasing an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 86.61% of the company’s stock.

A number of research analysts have weighed in on IDXX shares. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research report on Tuesday, October 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. BidaskClub downgraded shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Canaccord Genuity reiterated a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a research report on Friday, October 6th. Finally, Aegis reiterated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $173.67.

ILLEGAL ACTIVITY NOTICE: This report was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://theolympiareport.com/2018/01/12/insider-selling-idexx-laboratories-inc-idxx-ceo-sells-2160-shares-of-stock.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.